PH12022550496A1 - Methods of generating and isolating midbrain dopamine neurons - Google Patents

Methods of generating and isolating midbrain dopamine neurons

Info

Publication number
PH12022550496A1
PH12022550496A1 PH1/2022/550496A PH12022550496A PH12022550496A1 PH 12022550496 A1 PH12022550496 A1 PH 12022550496A1 PH 12022550496 A PH12022550496 A PH 12022550496A PH 12022550496 A1 PH12022550496 A1 PH 12022550496A1
Authority
PH
Philippines
Prior art keywords
methods
isolating
generating
dopamine neurons
midbrain dopamine
Prior art date
Application number
PH1/2022/550496A
Other languages
English (en)
Inventor
Stefan Irion
Taewan Kim
So Yeon Koo
Lorenz Studer
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of PH12022550496A1 publication Critical patent/PH12022550496A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PH1/2022/550496A 2019-08-29 2020-08-31 Methods of generating and isolating midbrain dopamine neurons PH12022550496A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893674P 2019-08-29 2019-08-29
PCT/US2020/048733 WO2021042027A1 (en) 2019-08-29 2020-08-31 Methods of generating and isolating midbrain dopamine neurons

Publications (1)

Publication Number Publication Date
PH12022550496A1 true PH12022550496A1 (en) 2023-03-20

Family

ID=74686069

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550496A PH12022550496A1 (en) 2019-08-29 2020-08-31 Methods of generating and isolating midbrain dopamine neurons

Country Status (13)

Country Link
US (1) US20220177835A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021477A4 (cg-RX-API-DMAC7.html)
JP (2) JP7759870B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051388A (cg-RX-API-DMAC7.html)
CN (2) CN114650836B (cg-RX-API-DMAC7.html)
AU (1) AU2020336221A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003826A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152522A1 (cg-RX-API-DMAC7.html)
IL (1) IL290930A (cg-RX-API-DMAC7.html)
MX (1) MX2022002532A (cg-RX-API-DMAC7.html)
PH (1) PH12022550496A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021042027A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202202994B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960527T3 (es) 2019-09-13 2024-03-05 Miltenyi Biotec Bv & Co Kg Método para la generación de una composición celular de células progenitoras dopaminérgicas del mesencéfalo ventral
EP4314256A1 (en) 2021-03-30 2024-02-07 Trailhead Biosystems Inc. Methods and compositions for generating oligodendrocyte progenitor cells
JP2024523738A (ja) 2021-07-14 2024-06-28 ノヴォ ノルディスク アー/エス ニューロンおよびその前駆体が富化された細胞集団を提供するための方法
CN115354028B (zh) * 2021-10-28 2023-05-23 中国科学院动物研究所 一种中脑多巴胺细胞群、其制造方法以及用途
KR20250040032A (ko) * 2022-07-21 2025-03-21 트레일헤드 바이오시스템즈 인크. 신경 전구체 세포로부터 인간 중뇌 도파민성 뉴런을 생성시키기 위한 방법 및 조성물
WO2024259119A2 (en) 2023-06-13 2024-12-19 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
AU2025217196A1 (en) 2024-01-31 2026-07-09 Bluerock Therapeutics Lp Igfbp2 in cell culture
CN117838835B (zh) * 2024-02-01 2024-11-08 暨南大学 成纤维细胞生长因子17蛋白和/或其激活剂在制备治疗阿尔兹海默病药物中的应用
WO2025252180A1 (zh) * 2024-06-05 2025-12-11 中国科学院脑科学与智能技术卓越创新中心 中脑多巴胺能祖细胞群的体外制备方法
WO2026039433A1 (en) * 2024-08-12 2026-02-19 Memorial Sloan-Kettering Cancer Center Midbrain dopaminergic neuron compositions and methods of use
WO2026096366A1 (en) 2024-10-28 2026-05-07 Bluerock Therapeutics Lp Compositions and methods for determination of pluripotent stem cell differentiability
CN119776284B (zh) * 2025-03-13 2025-06-20 首都医科大学宣武医院 含有多巴胺能荧光报告系统的细胞及异步共培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
US8642334B2 (en) * 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
WO2013015457A1 (en) * 2011-07-27 2013-01-31 Kyoto University Novel markers for dopaminergic neuron progenitor cells
AU2012332269B2 (en) * 2011-11-04 2018-05-31 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
CN121136933A (zh) * 2013-09-05 2025-12-16 国立大学法人京都大学 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒
EP3280426B1 (en) * 2015-04-09 2025-06-25 Biolamina AB Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
WO2016196661A1 (en) * 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
AU2017313065B2 (en) * 2016-08-16 2021-06-24 Fujifilm Cellular Dynamics Inc. Methods for differentiating pluripotent cells

Also Published As

Publication number Publication date
WO2021042027A1 (en) 2021-03-04
CN121227633A (zh) 2025-12-30
US20220177835A1 (en) 2022-06-09
CN114650836A (zh) 2022-06-21
EP4021477A1 (en) 2022-07-06
CN114650836B (zh) 2025-10-17
BR112022003826A2 (pt) 2022-05-31
MX2022002532A (es) 2022-06-16
JP7759870B2 (ja) 2025-10-24
JP2022546482A (ja) 2022-11-04
AU2020336221A1 (en) 2022-04-07
EP4021477A4 (en) 2023-12-13
JP2026001236A (ja) 2026-01-06
CA3152522A1 (en) 2021-03-04
IL290930A (en) 2022-04-01
ZA202202994B (en) 2022-12-21
KR20220051388A (ko) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
TN2023000250A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
BR112022003826A2 (pt) Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit
WO2021071788A3 (en) Oligonucleotide compositions and methods of use thereof
WO2020227691A3 (en) Oligonucleotide compositions and methods of use thereof
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020176597A9 (en) N-substituted indoles and other heterocycles for treating brain disorders
WO2020223538A8 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
WO2020252229A3 (en) Inhibitors of sarm1
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
PH12020552212A1 (en) Compositions and methods for the treatment of hemoglobinopathies and thalassemias
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
ZA202309516B (en) Anti-ccr8 antibodies
WO2023086428A3 (en) Novel modulators of the aryl hydrocarbon receptor and methods of use thereof
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
PH12021553249A1 (en) New heterocyclic compounds
WO2022232016A3 (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof